<SEC-DOCUMENT>0001193125-20-179128.txt : 20200625
<SEC-HEADER>0001193125-20-179128.hdr.sgml : 20200625
<ACCEPTANCE-DATETIME>20200625164632
ACCESSION NUMBER:		0001193125-20-179128
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200619
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200625
DATE AS OF CHANGE:		20200625

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330969592
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		20989850

	BUSINESS ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d924073d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): June&nbsp;19, 2020 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Inovio Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-14888</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">33-0969592</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State or other jurisdiction<BR>of incorporation)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Commission<BR>File Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>660 W. Germantown Pike, Suite 110 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Plymouth Meeting, PA 19462 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(267) <FONT STYLE="white-space:nowrap">440-4200</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&nbsp;12(b) of the Act: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading<BR>Symbol(s)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange<BR>on which
registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Common Stock, $0.001 par value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>INO</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The Nasdaq Stock Market LLC</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;1.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Entry into a Material Definitive Agreement. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;22, 2020, Inovio Pharmaceuticals, Inc. (the &#147;<B><I>Company</I></B>&#148;) entered into an Other Transaction Authority for Prototype Agreement
(the &#147;<B><I>OTA Agreement</I></B>&#148;) with the U.S. Department of Defense (the &#147;<B><I>DoD</I></B>&#148;) to fund the Company&#146;s efforts in developing its next-generation intradermal electroportation device, known as CELLECTRA<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> 3PSP, and associated arrays to be used for delivery of the Company&#146;s vaccine candidate, <FONT STYLE="white-space:nowrap">INO-4800,</FONT> as protection against
<FONT STYLE="white-space:nowrap">COVID-19.</FONT> Under the OTA Agreement, the Company intends to develop the CELLECTRA 3PSP device and arrays for use in the U.S. military population and the U.S. population as a whole, subject to approval of the
device by the U.S. Food and Drug Administration (the &#147;<B><I>FDA</I></B>&#148;). The OTA Agreement is also expected to support large-scale manufacturing of the CELLECTRA 3PSP device, as well as large-scale DNA plasmid production for manufacture
and supply of a specified number of doses of <FONT STYLE="white-space:nowrap">INO-4800</FONT> in support of FDA approval of the device. The total amount of funding being made available to the Company under the OTA Agreement is approximately
$54.5&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the OTA Agreement, the Company has agreed that, for a period of six years, it will not offer, sell or otherwise provide the
production model of the CELLECTRA 3PSP prototype to any entity at a price lower than that offered to the DoD. In addition, if the Company develops a commercialized version or derivative of the production model of the prototype with similar
capability and intended application, but at a lower unit price, the Company will be obligated to make the DoD aware of the similar product and the technical and price differences between the products, and no entity will be entitled to receive a
lower price than the DoD for similar purchase quantities of such product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DoD may, among other things, suspend or terminate the OTA Agreement if the
Company materially fails to comply with the provisions of the OTA Agreement after issuance of a cure notice and failure of the Company to cure the defect within a specified time. The DoD may also terminate the OTA Agreement in its discretion at any
time upon at least 30 days&#146; prior written notice to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, on June&nbsp;19, 2020, the Company was awarded a fixed-price contract
(the &#147;<B><I>Procurement Contract</I></B>&#148;) from the DoD for the purchase of the Company&#146;s intradermal CELLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> 2000 device and accessories. The CELLECTRA 2000 devices will be
used to inject <FONT STYLE="white-space:nowrap">INO-4800</FONT> in the Company&#146;s planned later-stage clinical trials. The total purchase price under the Procurement Contract is approximately $16.6&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the material terms of the OTA Agreement and the Procurement Contract does not purport to be complete and is qualified in its
entirety by reference to such agreements, which will be filed with the Securities and Exchange Commission as exhibits to the Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ending June&nbsp;30,
2020.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Regulation FD Disclosure. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;23, 2020, the Company issued a press release announcing the total funding of $71&nbsp;million being made available pursuant to the OTA Agreement
and the Procurement Contract. The funding is being provided by the DoD&#146;s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (&#147;<B><I>JPEO-CBRND</I></B>&#148;) and JPEO-CBRND&#146;s Joint Product Lead
CBNRD Enabling Technologies. A copy of this press release is furnished herewith as Exhibit 99.1 to this report. The information contained in the press release furnished as Exhibit 99.1 shall not be deemed &#147;filed&#148; for purposes of
Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;<B><I>Exchange Act</I></B>&#148;), and is not incorporated by reference into any of the Company&#146;s filings under the Securities Act of 1933, as amended, or the
Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Events. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;23, 2020, the Company established a new wholly-owned subsidiary, Inovio Asia LLC, established under the laws of South Korea, through which the
Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously announced, on
June 3, 2020, the Company filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania (the &#147;<B><I>Court</I></B>&#148;) seeking a preliminary injunction to compel VGXI, Inc. and GeneOne Life Science, Inc. (together,
&#147;<B><I>VGXI</I></B>&#148;) to facilitate the transfer of manufacturing methods, using VGXI&#146;s technology, under the parties&#146; existing supply agreement. On June 25, 2020, the Court denied the Company&#146;s petition for the preliminary
injunction. The Company is exploring its legal options, including a potential immediate appeal of the Court&#146;s decision. In addition, the Company is taking the next steps, including continuing discussions with third-party manufacturers,
necessary to support the rapid and large-scale manufacturing of INO-4800 to address the urgent global health need caused by the COVID-19 pandemic. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Forward-Looking Statements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This report contains
certain forward-looking statements relating to the Company&#146;s business that involve a number of risks and uncertainties, including statements related to expected development and manufacturing of its CELLECTRA 3PSP device and its vaccine
candidate <FONT STYLE="white-space:nowrap">INO-4800</FONT> and planned corporate activities in Asia. These statements may be identified by introductory </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
words such as &#147;may,&#148; &#147;expects,&#148; &#147;plan,&#148; &#147;believe,&#148; &#147;will,&#148; &#147;achieve,&#148; &#147;anticipate,&#148; &#147;would,&#148; &#147;should,&#148;
&#147;subject to&#148; or words of similar meaning, or by the fact that they do not relate strictly to historical or current facts. For such statements, the Company claims the protection of the Private Securities Litigation Reform Act of 1995.
Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including those discussed in the &#147;Risk Factors&#148; section of the Company&#146;s most recently filed Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> or Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> as well as other filings that the Company makes with the SEC from time to time. There can be no assurance that any of the
forward-looking information provided herein will be proven accurate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the forward-looking statements included in this report represent the
Company&#146;s views as of the date hereof. The Company anticipates that subsequent events and developments may cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future,
the company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company&#146;s views as of any date subsequent to the date of this report.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d924073dex991.htm">Press Release, dated June&nbsp;23, 2020. </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INOVIO PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: June&nbsp;25, 2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Kies</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Peter Kies</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d924073dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g924073g0625063509919.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INOVIO Receives $71 Million Contract From U.S. Department of </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Defense To Scale Up Manufacture of CELLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> 3PSP Smart </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Device and Procurement of CELLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> 2000 for
<FONT STYLE="white-space:nowrap">COVID-19</FONT> DNA Vaccine </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. Government will support the <FONT STYLE="white-space:nowrap">scale-up</FONT> of INOVIO&#146;s proprietary
intradermal DNA delivery device CELLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> 3PSP to deliver INOVIO&#146;s <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccine </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">INOVIO to report on interim US Phase 1 clinical trial results in late June </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">INOVIO preparing for U.S. Phase 2/3 efficacy study to begin this summer </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PLYMOUTH MEETING, PA &#150; June&nbsp;23, 2020 &#150; INOVIO (NASDAQ:INO) today announced it has received $71&nbsp;million funding from the U.S. Department of
Defense (DoD) to support the large-scale manufacture of the company&#146;s proprietary CELLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;3PSP smart device and the procurement of CELLECTRA<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> 2000 devices, which are used to deliver <FONT STYLE="white-space:nowrap">INO-4800&nbsp;directly</FONT> into the skin. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CELLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> 3PSP is designed to deliver <FONT STYLE="white-space:nowrap">INO-4800</FONT> directly into
the skin, where the vaccine prompts the body&#146;s immune system to drive a robust immune response. Interim results of U.S. Phase 1 clinical studies of <FONT STYLE="white-space:nowrap">INO-4800</FONT> will be available later this month. A Phase 2/3
efficacy trial is planned to begin this summer (July/August). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DoD contract, from the <FONT STYLE="white-space:nowrap">JPEO-CRBND-EB</FONT> through
funding provided by the Defense Health Program, builds upon two separate prior $5&nbsp;million grants from the Bill&nbsp;&amp; Melinda Gates Foundation and CEPI, to accelerate the testing of
CELLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> 3PSP. Initial development of this next generation CELLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> 3PSP smart device began in 2019 with&nbsp;$8.1 million&nbsp;in
funding from the medical arm of the U.S. Defense Threat Reduction Agency&#146;s Medical CBRN Defense Consortium. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;J. Joseph Kim, INOVIO&#146;s
President and CEO, said, &#147;INOVIO is very pleased to receive this significant funding from the U.S. Department of Defense to continue our rapid <FONT STYLE="white-space:nowrap">scale-up</FONT> capacity for our breakthrough DNA medicines delivery
device CELLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. We look forward to working closely with DoD, JPEO-CBRND and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">JPL-CBRND-EB</FONT></FONT> to provide much
needed protection to DoD </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
personnel and their families through development of a safe and effective vaccine against <FONT STYLE="white-space:nowrap">COVID-19.</FONT> This next generation smart device leverages the efficacy
delivery and safety track record of an earlier version that has received the CE mark certification and has been used in clinical trials to safely dose more than 2,000 patients in over 7,000 administrations of INOVIO&#146;s DNA medicines. The current
DoD contract further supports INOVIO&#146;s large-scale production of devices and arrays to deliver potentially hundreds of millions of doses of <FONT STYLE="white-space:nowrap">INO-4800</FONT> next year to combat the global <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CELLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> 3PSP is a small, portable,
hand-held, user-friendly device that runs on &#147;AA&#148; batteries. The device has been designed to function reliably in challenging environments and can be stockpiled in large quantities without maintenance, characteristics that are critical in
a pandemic situation. INOVIO&#146;s San Diego device manufacturing facility has produced initial quantities of the device, while also showing that the design and <FONT STYLE="white-space:nowrap">scale-up</FONT> of the manufacturing processes can be
transferred to contract manufacturers in order to further increase supply. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the JPEO-CBRND </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense is the Joint Service&#146;s lead for development, acquisition,
fielding and life-cycle support of chemical, biological, radiological and nuclear defense equipment and medical countermeasures. As an effective acquisition program, we put capable and supportable systems in the hands of the service members and
first responders, when and where it is needed, at an affordable price. Our vision is a resilient Joint Force enabled to fight and win unencumbered by a chemical, biological, radiological, or nuclear environment; championed by innovative and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> solutions. <FONT STYLE="white-space:nowrap">JPL-CBRND</FONT> Enabling Biotechnologies (EB) is an organization
established for the purpose of providing medical solutions, during a crisis, against future threats. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
<FONT STYLE="white-space:nowrap">INO-4800</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">INO-4800</FONT> is INOVIO&#146;s DNA vaccine candidate being
developed to protect against the novel coronavirus <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> which causes <FONT STYLE="white-space:nowrap">COVID-19.</FONT>
<FONT STYLE="white-space:nowrap">INO-4800</FONT> was designed using INOVIO&#146;s proprietary DNA medicine platform rapidly after the publication of the genetic sequence of the coronavirus that causes
<FONT STYLE="white-space:nowrap">COVID-19.</FONT> INOVIO has extensive experience working with coronaviruses and is the only company with a vaccine in Phase 2 development for a related coronavirus that causes Middle East Respiratory Syndrome (MERS).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">INO-4800</FONT> is the only nucleic-acid based vaccine that is stable at room temperature for more than a year and does
not require to be frozen in transport or storage, which are important factors when implementing mass immunizations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About INOVIO&#146;s DNA Medicines
Platform </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOVIO has 15 DNA medicine clinical programs currently in development focused on <FONT STYLE="white-space:nowrap">HPV-associated</FONT>
diseases, cancer, and infectious diseases, including coronaviruses associated with MERS and <FONT STYLE="white-space:nowrap">COVID-19</FONT> diseases being developed under grants from the Coalition for Epidemic Preparedness Innovations (CEPI) and
the DoD. DNA medicines are composed of optimized DNA plasmids, which are small circles of double-stranded DNA that are synthesized or reorganized by a computer sequencing technology and designed to produce a specific immune response in the body.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOVIO&#146;s DNA medicines deliver optimized plasmids directly into cells intradermally or intramuscularly
using INOVIO&#146;s proprietary hand-held smart device called CELLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. The CELLECTRA device uses a brief electrical pulse to reversibly open small pores in the cell to allow the plasmids to
enter, overcoming a key limitation of other DNA and other nucleic acid approaches, such as mRNA. Once inside the cell, the DNA plasmids enable the cell to produce the targeted antigen. The antigen is processed naturally in the cell and triggers the
desired T cell and antibody-mediated immune responses. Administration with the CELLECTRA device is designed to ensure that the DNA medicine is efficiently delivered directly into the body&#146;s cells, where it can go to work to drive an immune
response. INOVIO&#146;s DNA medicines do not interfere with or change in any way an individual&#146;s own DNA. The advantages of INOVIO&#146;s DNA medicine platform are how fast DNA medicines can be designed and manufactured, the stability of the
products which do not require freezing in storage and transport, and the robust immune response, safety profile, and tolerability that have been demonstrated in clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With more than 2,000 patients receiving INOVIO investigational DNA medicines in more than 7,000 applications across a range of clinical trials, INOVIO has a
strong track record of rapidly generating DNA medicine candidates with potential to meet urgent global health needs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>About INOVIO </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases,
cancer, and diseases associated with HPV. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable
immune response. Specifically, INOVIO&#146;s lead candidate <FONT STYLE="white-space:nowrap">VGX-3100,</FONT> currently in Phase 3 trials for precancerous cervical dysplasia, destroyed and cleared high-risk HPV 16 and 18 in a Phase 2b clinical
trial. High-risk HPV is responsible for 70% of cervical cancer, 91% of anal cancer, and 69% of vulvar cancer. Also in development are programs targeting <FONT STYLE="white-space:nowrap">HPV-related</FONT> cancers and a rare <FONT
STYLE="white-space:nowrap">HPV-related</FONT> disease, recurrent respiratory papillomatosis (RRP); <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-HPV-related</FONT></FONT> cancers glioblastoma multiforme (GBM) and prostate
cancer; as well as externally funded infectious disease DNA vaccine development programs in Zika, Lassa fever, Ebola, HIV, and coronaviruses associated with MERS and <FONT STYLE="white-space:nowrap">COVID-19</FONT> diseases. Partners and
collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill&nbsp;&amp; Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA)/Department of Defense (DOD),
GeneOne Life Science/VGXI, HIV Vaccines Trial Network, International Vaccine Institute (IVI), Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases,
Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Roche/Genentech, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. INOVIO also
is a proud recipient of 2020 Women on Boards &#147;W&#148; designation recognizing companies with more than 20% women on their board of directors. For more information, visit www.inovio.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>CONTACTS: </U></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Media:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Jeff Richardson, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">267-440-4211,</FONT></FONT>
jrichardson@inovio.com </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Investors:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ben Matone, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">484-362-0076,</FONT></FONT>
ben.matone@inovio.com </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains certain forward-looking statements relating to our business, including our
plans to develop DNA medicines, our expectations regarding our research and development programs, including the availability and timing of data from the company&#146;s ongoing Phase 1 clinical trial of
<FONT STYLE="white-space:nowrap">INO-4800</FONT> and the company&#146;s plans and ability to outsource manufacturing of its delivery devices to contract manufacturers. Actual events or results may differ from the expectations set forth herein as a
result of a number of factors, including uncertainties inherent in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, clinical trials, product development programs and commercialization activities and outcomes, the availability of funding
to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of
our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, our ability to secure adequate third-party manufacturing resources for the
production of our product candidates, including the transfer of necessary processes, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our
collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or
licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of
invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or
collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2019, our Quarterly
Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2020 and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in
our pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein
will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law. </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g924073g0625063509919.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g924073g0625063509919.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "$ 68# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!Y@7=*?5SR?\/PKCOBM_JM+^LO\ ): /0K>9;FUBG4$+*@< ]0",U+532O\
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MJ"NC^?I\C>_ER>Q'\+?YYKTK1M8M=<TZ.]M&RK<,I^\C=P: -"BBB@ HHHH
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M^ ?^A"@"O\.?^10B_P"NTG_H5=)>WUKIUI)=7DZ0P1C+.YP!7-_#G_D4(O\
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M\44C[$W>I/MP:KW6AR7B^;XQU^/R?O?8H9!# /J3RU:X:G2<Y2:LM$M==/\
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MZ_U'0_C7K%<+\3M,6?1X-05?WEO)L8C^XW_U\?G0!W5%8OA+43JGABQN'.9
MGEN?]I>#_*MJ@ HHHH **** /+==_P"2LV?_ %VM_P"E>I5Y;KO_ "5FS_Z[
M6_\ 2O4J .-^)G_(KQ_]?2?R:M+P1_R)NF_]<S_Z$:S?B9_R*\?_ %])_)JT
MO!'_ ")NF_\ 7,_^A&@#H*YWQ=X9C\0Z=^["I?0@F&0]_P#9/L?TKHJ* /,?
M _B:33+O^P=5+1H'*1&3@Q/G[A]B>E>G5PWCSPG_ &C"VJV,>;R)?WJ*/]:H
M[_[P_6G> _%G]I0+I=])_ID2_NG8_P"M4?\ LP_7\Z .WKF_'O\ R)M]_P
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MMK>.")=L<:A%'H ,"I*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
9BB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
